HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. (scientific article published on 07 August 2009)

Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein

Q27651983

Maturation inhibitors: a new therapeutic class targets the virus structure

Q28256231

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

Q28318483

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

Q28323197

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

Q28369297

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

Q28474984

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

Q29547734

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Q29619254

Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease

Q30850215

A stiffness switch in human immunodeficiency virus

Q33266091

Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag).

Q33807166

Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells

Q33845811

The stoichiometry of Gag protein in HIV-1.

Q34328141

Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication

Q34364648

Viral protease inhibitors

Q34892265

Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity

Q35838533

Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression

Q35980829

Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1

Q36098898

Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis

Q36266587

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Q36650046

Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration

Q36916993

Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity

Q36944098

Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation

Q36944553

Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation

Q36958798

Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase

Q37060306

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

Q37089562

Protease inhibitor plasma concentrations in HIV antiretroviral therapy

Q37397695

Maturation of the viral core enhances the fusion of HIV-1 particles with primary human T cells and monocyte-derived macrophages

Q39106404

Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Q39579012

Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1.

Q39588178

Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles

Q39593215

HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor

Q39872885

Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative

Q39991984

The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Q40042979

Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation

Q40049266

Double-labelled HIV-1 particles for study of virus-cell interaction.

Q40209637

Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag.

Q40326740

Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail

Q40579232

Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism

Q41275889

Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease

Q41997191

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

Q45746500

Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles

Q45773050

Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange.

Q47314618

Mutation of the major 5' splice site renders a CMV-driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing.

Q47822116

A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Q50498229

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

HIV

Q15787

infectivity

Q1662346

P304

page(s)

29692-29703

P577

publication date

2009-08-07

P1433

published in

Journal of Biological Chemistry

Q867727

P1476

title

HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity

P478

volume

284

Reverse relations

cites work (P2860)

Q41730903	A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro
Q40618525	A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny
Q36369127	A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs
Q40047295	A novel HIV vaccine targeting the protease cleavage sites
Q35812907	A quantitative basis for antiretroviral therapy for HIV-1 infection
Q34771244	A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid
Q27324263	Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors
Q51740197	An RNA-binding compound that stabilizes the HIV-1 gRNA packaging signal structure and specifically blocks HIV-1 RNA encapsidation.
Q30455050	Assembly and architecture of HIV.
Q33619173	Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag
Q33761008	Cryo electron tomography of native HIV-1 budding sites
Q30425900	Design of in vitro symmetric complexes and analysis by hybrid methods reveal mechanisms of HIV capsid assembly
Q42225067	Determination of the protease cleavage site repertoire--the RNase H but not the RT domain is essential for foamy viral protease activity
Q33791156	Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity
Q92623235	Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes
Q35416123	Electron cryotomography studies of maturing HIV-1 particles reveal the assembly pathway of the viral core
Q36434250	Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain
Q41701451	Envelope glycoprotein mobility on HIV-1 particles depends on the virus maturation state
Q34775654	Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function
Q34237075	Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications
Q27309923	Fusion of mature HIV-1 particles leads to complete release of a gag-GFP-based content marker and raises the intraviral pH
Q28533696	Gag-Pol processing during HIV-1 virion maturation: a systems biology approach
Q31106756	Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.
Q24614498	HIV type 1 Gag as a target for antiviral therapy
Q36755310	HIV-1 Gag Blocks Selenite-Induced Stress Granule Assembly by Altering the mRNA Cap-Binding Complex
Q58597952	HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites
Q38366763	HIV-1 gag: an emerging target for antiretroviral therapy.
Q92495399	HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions
Q57050142	High-resolution structures of HIV-1 Gag cleavage mutants determine structural switch for virus maturation
Q34626162	Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assembly
Q38032330	Human Immunodeficiency Virus Gag and protease: partners in resistance
Q36256762	Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein
Q57459053	Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation
Q51002244	Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.
Q35107346	Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.
Q35184863	In vitro analysis of human immunodeficiency virus particle dissociation: gag proteolytic processing influences dissociation kinetics
Q41735307	Induced maturation of human immunodeficiency virus.
Q38626145	Inhibitors of Deubiquitinating Enzymes Block HIV-1 Replication and Augment the Presentation of Gag-Derived MHC-I Epitopes.
Q41454699	LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions
Q35477673	Lentiviral Gag assembly analyzed through the functional characterization of chimeric simian immunodeficiency viruses expressing different domains of the feline immunodeficiency virus capsid protein
Q30613887	Maturation of the HIV-1 core by a non-diffusional phase transition.
Q42288273	Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy
Q58699804	Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques
Q35237575	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.
Q35105780	Novel dengue virus NS2B/NS3 protease inhibitors
Q36414162	Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.
Q34260135	Pokeweed antiviral protein increases HIV-1 particle infectivity by activating the cellular mitogen activated protein kinase pathway
Q40732172	RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly
Q38393674	Retroviral proteases and their roles in virion maturation
Q26752271	Retrovirus maturation-an extraordinary structural transformation
Q28710568	Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity
Q92490664	Second Generation Inhibitors of HIV-1 Maturation
Q34614167	Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription
Q33720677	Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer
Q47624537	Specific reverse transcriptase slippage at the HIV ribosomal frameshift sequence: potential implications for modulation of GagPol synthesis
Q33769181	Structural analysis of HIV-1 maturation using cryo-electron tomography
Q35024116	Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy
Q28076985	The Life-Cycle of the HIV-1 Gag-RNA Complex
Q33727091	The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation
Q27009643	The choreography of HIV-1 proteolytic processing and virion assembly
Q39621109	Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity
Q52339521	Transmission genetics of drug-resistant hepatitis C virus.
Q41442854	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor

P356	DOI	10.1074/JBC.M109.027144
P932	PMC publication ID	2785601
P698	PubMed publication ID	19666477